ABBISKO-B Reveals Phase II Data for Combination Therapy in FGFR2-Positive Gastric Cancer at ASCO 2026

Stock News

Jun 26

ABBISKO-B (ASX: 02256) has issued an announcement. The company's subsidiary, Shanghai Abbisko Biomedical Technology Co., Ltd. (Abbisko Medical), announced the presentation of preliminary results from a Phase II clinical study at the recent 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.

The study evaluated its self-developed, first-in-class oral highly selective FGFR2/3 inhibitor ABSK061 in combination with the oral PD-L1 inhibitor ABSSK043, with or without CAPOX (oxaliplatin combined with capecitabine), for the treatment of FGFR2-positive advanced gastric cancer and gastroesophageal junction cancer (GC/GEJC).

The research data indicates that the combination of ABSK061 and ABSSK043, with or without CAPOX, demonstrated a favorable safety profile and promising anti-tumor activity in patients with FGFR2-positive advanced GC/GEJC. These results highlight the potential of this targeted combination immunotherapy strategy as a novel treatment option for this patient population.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/1172651509"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1172651509\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1172651509?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-26 12:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1172651509","market":"us","top_or_hot":-1,"title":"ABBISKO-B Reveals Phase II Data for Combination Therapy in FGFR2-Positive Gastric Cancer at ASCO 2026","media":"Stock News","content":"<p>ABBISKO-B (<b>ASX: 02256</b>) has issued an announcement. The company's subsidiary, Shanghai Abbisko Biomedical Technology Co., Ltd. (Abbisko Medical), announced the presentation of preliminary results from a Phase II clinical study at the recent 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.<br><br>The study evaluated its self-developed, first-in-class oral highly selective FGFR2/3 inhibitor ABSK061 in combination with the oral PD-L1 inhibitor ABSSK043, with or without CAPOX (oxaliplatin combined with capecitabine), for the treatment of FGFR2-positive advanced gastric cancer and gastroesophageal junction cancer (GC/GEJC).<br><br>The research data indicates that the combination of ABSK061 and ABSSK043, with or without CAPOX, demonstrated a favorable safety profile and promising anti-tumor activity in patients with FGFR2-positive advanced GC/GEJC. These results highlight the potential of this targeted combination immunotherapy strategy as a novel treatment option for this patient population.<br><br></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ABBISKO-B Reveals Phase II Data for Combination Therapy in FGFR2-Positive Gastric Cancer at ASCO 2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nABBISKO-B Reveals Phase II Data for Combination Therapy in FGFR2-Positive Gastric Cancer at ASCO 2026\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-06-26 12:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>ABBISKO-B (<b>ASX: 02256</b>) has issued an announcement. The company's subsidiary, Shanghai Abbisko Biomedical Technology Co., Ltd. (Abbisko Medical), announced the presentation of preliminary results from a Phase II clinical study at the recent 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.<br><br>The study evaluated its self-developed, first-in-class oral highly selective FGFR2/3 inhibitor ABSK061 in combination with the oral PD-L1 inhibitor ABSSK043, with or without CAPOX (oxaliplatin combined with capecitabine), for the treatment of FGFR2-positive advanced gastric cancer and gastroesophageal junction cancer (GC/GEJC).<br><br>The research data indicates that the combination of ABSK061 and ABSSK043, with or without CAPOX, demonstrated a favorable safety profile and promising anti-tumor activity in patients with FGFR2-positive advanced GC/GEJC. These results highlight the potential of this targeted combination immunotherapy strategy as a novel treatment option for this patient population.<br><br></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2778985437.USD","symbol_name":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"A\" (USD) INC","start_time":0,"source_url":"","article_id":"1172651509","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1172651509","pubTimestamp":1782448459,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"ABBISKO-B (ASX: 02256) has issued an announcement. The company's subsidiary, Shanghai Abbisko Biomedical Technology Co., Ltd. (Abbisko Medical), announced the presentation of preliminary results from...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159938":"医药","LU2778985437.USD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"A\" (USD) INC","IE00B543WZ88.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC","02256":"和誉-B","IE00B5MMRT66.SGD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (SGDHDG) ACC","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU2476274720.SGD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"AT\" (SGDHDG) ACC","LU2476274308.USD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"AT\" (USD) ACC","BK1515":"抗疫概念","BK1161":"生物科技","BK1574":"生物医药B类股","09939":"开拓药业-B","IE00BPRC5H50.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) INC"},"translate_title":"ABBISKO-B在ASCO 2026上公布FGFR2阳性胃癌联合治疗II期数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159938":1,"09939":1,"02256":1},"content_text":"ABBISKO-B (ASX: 02256) has issued an announcement. The company's subsidiary, Shanghai Abbisko Biomedical Technology Co., Ltd. (Abbisko Medical), announced the presentation of preliminary results from a Phase II clinical study at the recent 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.The study evaluated its self-developed, first-in-class oral highly selective FGFR2/3 inhibitor ABSK061 in combination with the oral PD-L1 inhibitor ABSSK043, with or without CAPOX (oxaliplatin combined with capecitabine), for the treatment of FGFR2-positive advanced gastric cancer and gastroesophageal junction cancer (GC/GEJC).The research data indicates that the combination of ABSK061 and ABSSK043, with or without CAPOX, demonstrated a favorable safety profile and promising anti-tumor activity in patients with FGFR2-positive advanced GC/GEJC. These results highlight the potential of this targeted combination immunotherapy strategy as a novel treatment option for this patient population.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}